Schizophrenia & Other Psychotic Disorders
Hard Talk
Schizophrenia and postmodernism: A philosophical exercise in treatment
A psychiatrist who understands and appreciates postmodernism can show a patient why at some level we cannot refute all delusions.
From the Journals
Clozapine may be best choice for cutting SUD risk in schizophrenia
Research on the effectiveness of pharmacotherapies for schizophrenia and comorbid substance use disorder is “very sparse.”
From the Journals
Baseline neuromotor abnormalities persist in schizophrenia
Long-term follow-up data showed predictive value of dyskinesia and neurological soft signs for neuromotor dysfunction.
From the Journals
Subtle visual dysfunctions often precede early-stage psychosis
Unlike patients with nonpsychotic disorders, approximately 50%-60% of patients diagnosed with schizophrenia report visual dysfunctions.
Evidence-Based Reviews
Neuropsychiatric symptoms after stroke
Accurate identification is vital to optimizing recovery and quality of life.
Pearls
Preparing patients with serious mental illness for extreme HEAT
Climate change is causing intense heat waves that threaten human health across the globe.
From the Journals
Brief Psychiatric Rating Scale succeeds as transdiagnostic measure
The BPRS showed solid correlation with the mini-ICF-APP for disorders in six different categories.
Latest News
APA task force highlights U.S. psychiatric bed crisis
The APA’s virtual model will be continually updated and can be modified to better reflect the current situation in any given community.
Opinion
Postpartum psychosis: Does longitudinal course inform treatment?
The good news is we’ve seen an evolution of both interest and expertise in acute management of postpartum psychosis and a richer appreciation of...
From the Journals
LAIAs safer, more effective than oral antipsychotics for schizophrenia
“There may be a unique benefit to transitioning to long-acting injectable antipsychotics within the first 2 years of illness,” said Dr. Brittany...
Latest News
Positive phase 3 results for novel schizophrenia drug
The findings could “potentially usher in the first new class of medicine for these patients in more than 50 years.”